Search

Search Constraints

You searched for: Author/Creator Rossi, Francesca Maria

Search Results

1. Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. Issue 5 (24th February 2021)

2. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Issue 2 (2nd October 2012)

3. Clinical significance of c.7544‐7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia. (20th November 2012)

4. Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases. (28th January 2021)

5. COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. Issue 5 (30th August 2021)

6. Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials. Issue 8 (3rd May 2021)

7. Elastin MIcrofibriL INterfacer1 (EMILIN‐1) is an alternative prosurvival VLA‐4 ligand in chronic lymphocytic leukemia. Issue 2 (22nd November 2021)

8. PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus‐related diseases. (29th December 2020)

9. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Issue 8 (25th May 2021)